ArticleRespiration; international review of thoracic diseases2022
The Effect of Borderline Pulmonary Hypertension on Survival in Chronic Lung Disease.
Article in Respiration; international review of thoracic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 48 citations in OpenAlex.
- Pulmonary vascular reactivity in severe pulmonary hypertension associated with COPD.ERJ open research · 2026Article
- Navigating the Complexity of PH-ILD: From Molecular Mechanisms to Integrated Clinical Evaluation.International journal of molecular sciences · 2026Review
- Development and internal validation of a nomogram to predict pulmonary hypertension in fibrosing interstitial lung diseases.BMC pulmonary medicine · 2026Article
- Pathogenesis and Phenotypes of Pulmonary Vascular Disease in COPD: A Consensus Statement From the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - PH Group 3 Workstream.Pulmonary circulation · 2026Article
- Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review.The European respiratory journal · 2026Review
- Assessment of noninvasive parameters prior to diagnosis of pulmonary hypertension in patients with fibrotic interstitial lung disease.ERJ open research · 2026Article
- Prevalence, pathogenesis, and clinical impact of pulmonary hypertension associated with chronic obstructive pulmonary disease.Frontiers in cardiovascular medicine · 2026Review
- Survival in patients with pulmonary hypertension associated with fibrotic interstitial lung disease (ILD) is independent of ILD subtype.ERJ open research · 2025Article
- A 10,000-Foot View at Survival and Treatment with Phosphodiesterase-5 Inhibitors in Interstitial Lung Disease Pulmonary Hypertension.American journal of respiratory and critical care medicine · 2025Article
- Real-World Comparison of Patients With PH-ILD Initiating Inhaled Treprostinil Versus Patients Who Remain Untreated.Pulmonary circulation · 2025Article
- Significance of Pulmonary Vascular Dysfunction in Chronic Obstructive Pulmonary Disease.Pulmonary circulation · 2025Review
- Comorbidities' Effect on IPF: Pathogenesis and Management.Biomedicines · 2025Review
- Serial Pulmonary Hemodynamics in Patients with Idiopathic Pulmonary Fibrosis Listed for Lung Transplant.American journal of respiratory and critical care medicine · 2025Article
- Article
- Right Heart Catheterization Accurately Diagnoses Pulmonary Hypertension in Patients With Interstitial Lung Disease: Results From a Long-Term Cohort Study.Pulmonary circulation · 2025Article
- Preacinar Arterial Dilation Mediates Outcomes of Quantitative Interstitial Abnormalities in the COPDGene Study.American journal of respiratory and critical care medicine · 2024Article
- Imaging the Intersection of Parenchymal Abnormalities and Pulmonary Vascular Pathways.American journal of respiratory and critical care medicine · 2024Article
- Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH-CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative-group 3 pulmonary hypertension.Pulmonary circulation · 2024Review
- Pulmonary hypertension associated with lung diseases.The European respiratory journal · 2024Review
- COPD associated pulmonary hypertension: A post hoc analysis of the PERFECT study.Pulmonary circulation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of the new "borderline" hemodynamic class for pulmonary hypertension (PH) (mean pulmonary artery pressure [mPAP], 21-24 mm Hg and pulmonary vascular resistance, [PVR], ≥3 wood units, [WU]) in chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) is unclear.
objectivesThe aim of this study was to assess the effect of borderline PH (BLPH) on survival in COPD and ILD patients.
methodSurvival was analyzed from retrospective data from 317 patients in 12 centers (Italy, Spain, UK) comparing four hemodynamic groups: the absence of PH (NoPH; mPAP <21 mm Hg or 21-24 mm Hg and PVR <3 WU), BLPH (mPAP 21-24 mm Hg and PVR ≥3 WU), mild-moderate PH (MPH; mPAP 25-35 mm Hg and cardiac index [CI] ≥2 L/min/m2), and severe PH (SPH; mPAP ≥35 mm Hg or mPAP ≥25 mm Hg and CI <2 L/min/m2).
resultsBLPH affected 14% of patients; hemodynamic severity did not predict survival when COPD and ILD patients were analyzed together. However, survival in the ILD cohort for any PH level was worse than in NoPH (3-year survival: NoPH 58%, BLPH 32%, MPH 28%, SPH 33%, p = 0.002). In the COPD cohort, only SPH had reduced survival compared to the other groups (3-year survival: NoPH 82%, BLPH 86%, MPH 87%, SPH 57%, p = 0.005). The mortality risk correlated significantly with mPAP in ILD (hazard ratio [HR]: 2.776, 95% CI: 2.057-3.748, p < 0.001) and notably less in COPD patients (HR: 1.015, 95% CI: 1.003-1.027, p = 0.0146).
conclusionsIn ILD, any level of PH portends worse survival, while in COPD, only SPH presents a worse outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.